Quantcast

Latest Insulin glargine Stories

2010-04-01 07:30:00

JERSEY CITY, N.J., April 1 /PRNewswire/ -- Diabetes is a national epidemic. In the United States, a person is diagnosed with diabetes every 21 seconds. A new interactive traveling exhibit, Diabetes: A Deeper Look, developed by the Detroit Science Center and made possible with support from sanofi-aventis U.S., will help hundreds of thousands of people across the country understand diabetes, available diabetes treatment options, and the role insulin plays in the body. Opening today at...

2010-03-31 00:00:00

SALEM, N.H., March 31 /PRNewswire/ -- AgaMatrix, Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix's WaveSense(TM) technology. Sanofi-aventis will commercialize through its Global...

2010-03-02 12:09:25

The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ from each other when it comes to their influence on cancer risk. Cancer expert Professor Michael Pollak from McGill University, Montreal, Canada, teamed up with diabetes expert Professor David Russell-Jones from The Royal Surrey County Hospital, Guildford, UK, to review more...

2009-12-03 08:18:00

WALTHAM, Mass., Dec. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013. The projected 15 percent annual growth rate is attributed to a growing prevalent and drug-treated population, increased use of new generation antidiabetics such as Merck's Januvia, Novartis's Galvus,...

2009-11-03 10:40:00

NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes http://www.reportlinker.com/p0157514/Commercial-Insight-Antidiabetics-in-Australia---Reimbursement-status-shapes-novel-classes.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Introduction The author expects the Australian antidiabetics market to...

2009-10-20 07:30:00

PRINCETON, N.J., Oct. 20 /PRNewswire-FirstCall/ -- A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin(1,2). The analysis conducted by Novo Nordisk assessed the relative risk...

2009-09-30 01:30:00

PARIS, September 30 /PRNewswire-FirstCall/ -- - 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R) Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the...

2009-08-11 10:08:24

Accumulating safety data from the large, international ORIGIN trial have been reviewed by its independent data monitoring committee, who have concluded that there is no cause for concern.This six-year study, which is lead by McMaster University professors Dr. Hertzel Gerstein and Dr. Salim Yusuf of the Population Health Research Institute, is determining whether insulin glargine and/or omega 3 fatty acids can reduce cardiovascular events in 12,578 people with elevated blood sugar levels from...

2009-07-29 06:00:00

BRIDGEWATER, N.J., July 29 /PRNewswire-FirstCall/ -- Change Change Change at Change at on a constant on a constant Q2 reported exchange reported exchange 2009 basis rates H1 2009 basis rates ------- --------- -------- ------- -------...

2009-07-20 15:14:00

SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus((R)) (insulin glargine). Patients randomized to exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months, of...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related